hold on there's just too much going on in Congress lmao...
Requires regular updates to medical guidance for treating PFAS-related health effects.
Introduced by Ms. Dexter and Mr. Lawler in the House of Representatives.
Introduced in the House, referred to committee.
This bill mandates the Agency for Toxic Substances and Disease Registry (ATSDR) to contract with the National Academies to periodically assess PFAS health effects and recommend clinical guidance. This guidance would then be issued and disseminated to healthcare professionals and public health authorities. The bill was introduced by Representative Dexter and Representative Lawler and is currently awaiting review in a House committee, a common first step for new legislation.
Introduced Jan 8, 2026
The bill was introduced in the House of Representatives on January 8, 2026, and referred to the House Committee on Energy and Commerce. Before it can become law, it must pass through this committee, be voted on and passed by the full House, then go through a similar process in the Senate, and finally be signed by the President.
If this bill passes, the Agency for Toxic Substances and Disease Registry (ATSDR) would be required to ensure that medical professionals and public health bodies receive updated clinical guidance on addressing the health effects of PFAS. This means doctors you visit would ideally have access to the latest research and recommendations for diagnosing, testing, and treating conditions linked to PFAS exposure, potentially leading to more informed care. State and local public health authorities would also disseminate this guidance, helping to standardize responses to PFAS concerns.
Supporters Say
Supporters would argue this bill ensures healthcare providers are equipped with the latest scientific knowledge to treat patients exposed to harmful PFAS chemicals.
Critics Say
Critics might suggest that existing agencies already have mechanisms for updating guidance, or that funding could be better used for source mitigation.
Those in favor would highlight the importance of providing current, evidence-based guidance to doctors, ensuring that individuals exposed to PFAS receive the best possible care as scientific understanding evolves. They might emphasize the need for regular updates given the ongoing research into PFAS. Potential concerns could include the cost of the mandated assessments and agreements, or whether the current system for medical guidance updates is sufficient without new legislation.